Find a Doctor
As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, the adverse effects of cancer treatment, and HPV (Human Papilloma Virus) - related oral cancers. Dr. Trotti is currently leading the largest international trial testing a reduced toxicity agent (cetuximab) in HPV-related oral cancers. This study has enrolled 900 patients at 85 centers and initial results are expected in 2017. He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 25 years. Dr. Trotti was recognized as Clinical Educator of the Year at Moffitt in 2010. He has also delivered several honorary lectures including the keynote address at the American Head and Neck Society and the Wharton Lecture at Princess Margaret Hospital. Under his leadership, Moffitt became a member of the National Cancer Institute-sponsored Radiation Therapy Oncology Group (RTOG) in 1990 and continues today as one of a select group of active full members. Dr. Trotti serves as institutional principal investigator for RTOG studies. Dr. Trotti is co-chair of the RTOG Head and Neck Committee. Under his guidance, several of his radiation oncology colleagues at Moffitt have participated in leadership roles within RTOG, including the Quality of Life Committee, Outcomes Committee, Special Populations Committee, and Research Associates Committee. As part of the effort to measure outcomes, Darlene Johnson, MBA and Dr. Trotti developed and validated a radiation-specific quality of life tool used in two national RTOG trials. Dr. Trotti and colleague Dr. Javier Torres-Roca were awarded a pilot grant to study genomic predictors of radiosensitivity in RTOG populations. Dr. Trotti has served as co-chair of the Health Services Research (HSR) Committee for both the American Society of Therapeutic Radiology and Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO). Dr. Trotti has a unique area of expertise: the recognition, reporting, prevention, and management of the adverse effects of cancer treatment. Dr. Trotti assisted the NCI in creating the current NCI dictionary for adverse events (CTCAE). This document has become the international standard language for toxicity reporting. He has also led pivotal trials testing iseganan and lisofylline in mucositis. Dr. Trotti and colleagues were awarded federal grants to develop electronic methods of grading and reporting toxicity in clinical trials (Safety Profiler).
Education & Training
Start Year: 2010 End Year: Clinician Educator of the Year, Sponsor: Moffitt Cancer Center
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including: